Free Trial
NASDAQ:MAZE

Maze Therapeutics (MAZE) Stock Price, News & Analysis

Maze Therapeutics logo
$13.49 +0.26 (+1.97%)
As of 08/22/2025 04:00 PM Eastern

About Maze Therapeutics Stock (NASDAQ:MAZE)

Key Stats

Today's Range
$13.30
$14.02
50-Day Range
$10.33
$17.78
52-Week Range
$6.71
$19.19
Volume
263,956 shs
Average Volume
172,630 shs
Market Capitalization
$591.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.60
Consensus Rating
Buy

Company Overview

Receive MAZE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MAZE Stock News Headlines

Leerink Partnrs Expects Lower Earnings for Maze Therapeutics
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
HC Wainwright Lifts Earnings Estimates for Maze Therapeutics
See More Headlines

MAZE Stock Analysis - Frequently Asked Questions

Maze Therapeutics' stock was trading at $13.38 at the beginning of 2025. Since then, MAZE stock has increased by 0.8% and is now trading at $13.49.

Maze Therapeutics, Inc. (NASDAQ:MAZE) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Maze Therapeutics (MAZE) raised $140 million in an initial public offering on Friday, January 31st 2025. The company issued 8,750,000 shares at a price of $16.00 per share.

Maze Therapeutics's lock-up period expired on Wednesday, July 30th. Maze Therapeutics had issued 8,750,000 shares in its public offering on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Maze Therapeutics' top institutional shareholders include Frazier Life Sciences Management L.P. (10.42%), Geode Capital Management LLC (0.53%), Octagon Capital Advisors LP (0.41%) and Boothbay Fund Management LLC (0.17%).

Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/12/2025
Today
8/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MAZE
Previous Symbol
NASDAQ:MAZE
CIK
1842295
Web
N/A
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

High Price Target
$34.00
Low Price Target
$17.00
Potential Upside/Downside
+89.8%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.63
Quick Ratio
13.63

Sales & Book Value

Annual Sales
$2.50 million
Price / Sales
236.62
Cash Flow
$0.16 per share
Price / Cash Flow
86.42
Book Value
$5.98 per share
Price / Book
2.26

Miscellaneous

Outstanding Shares
43,851,000
Free Float
N/A
Market Cap
$591.55 million
Optionable
N/A
Beta
N/A

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:MAZE) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners